Abstract
Background
While sentinel lymph node dissection (SLND) provides axillary staging, recent trials question the necessity of removing positive nonsentinel axillary lymph nodes (LN) in breast cancer. We sought to determine the technical feasibility of percutaneous core needle biopsy (PNB) of axillary sentinel lymph nodes (SLNs).
Methods
After dual tracer injection, 25 patients underwent intraoperative axillary ultrasound and ultrasound guided per PNB of the axillary LN at the site of radiotracer uptake, followed by standard SLND. The primary outcome measure was successful correlation of PNB with SLN, defined as: (1) similar final pathology in core and SLN and (2) presence of blue staining and/or radiotracer in the core or gross evidence of PNB at the SLN (e.g., transected SLN).
Results
Preincision axillary ultrasound identified a LN (mean size 1.15 ± 0.67 cm) at the site of radioactive tracer in 92 % (23 of 25) of cases. Gross evidence of PNB at the SLN was found in 76 % (19 of 25) of cases. Blue staining, radioisotope, and pathology matched in core and SLN specimens in 36 % (9 of 25), 64 % (16 of 25), and 72 % (18 of 25) of cases, respectively. Overall, successful correlation of core biopsy with SLN occurred in 72 % (18 of 25) of cases.
Conclusions
Results of this phase I study demonstrate that PNB of the SLN is technically feasible, but further refinement of technique is warranted to improve correlation of core biopsy to SLND.
Similar content being viewed by others
References
Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early stage breast cancer. J Clin Oncol. 2005;23:7703–20.
Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;39:546–53.
Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927–33.
Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J Natl Cancer Inst. 2006;98:599–609.
Krag DN, Anderson JS, Julian TB, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;210:881–8.
Schrenk P, Rieger R, Shamiyeh A, Wayand W. Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. Cancer. 2000;88:608–14.
Burak WE, Hollenbeck ST, Zervos EE, Hock KL, Kemp LC, Young DC. Sentinel lymph node biopsy results in less postoperative morbidity compared with axillary lymph node dissection for breast cancer. Am J Surg. 2002;183:23–7.
Haid A, Koberle-Wuhrer R, Knauer M, et al. Morbidity of breast cancer patients following complete axillary dissection or sentinel node biopsy only: a comparative evaluation. Breast Cancer Res Treat. 2002;73:31–6.
Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569–75.
Donker M, Van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicenter, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15:1303–10.
Szemere Boughey JC. Lymph Node Dissection and Radiation Therapy in Treating Patients with Breast Cancer Previously Treated with Chemotherapy and Surgery: Alliance 11202. http://www.cancer.gov/about-cancer/treatment/clinical trials/search/view?cdrid=751211. Accessed 25 Mar 2016.
Mamounas EP. Standard or Comprehensive Radiation Therapy in Treating Patients with Early-Stage Breast Cancer Previously Treated with Chemotherapy and Surgery. NSABP B-51/RTOG 1304 http://www.cancer.gov/about-cancer/treatment/clinical-trials/search/view?cdrid=750327. Accessed 25 Mar 2016.
Xie F, Zhang D, Cheng L, et al. Intradermal microbubbles and contrast-enhanced ultrasound (CEUS) is a feasible approach for sentinel lymph node identification in early-stage breast cancer. World J Surg Oncol. 2016;13:319.
Cox K, Sever A, Jones S, et al. Validation of a technique using microbubbles and contrast enhanced ultrasound (CEUS) to biopsy sentinel lymph nodes (SLN) in pre-operative breast cancer patients with a normal grey-scale axillary ultrasound. Eur J Surg Oncol. 2013;39:760–5.
Whelehan P, Vinnicombe SJ, Brown DC, McLean D, Evans A, Accuracy of non-operative identification of the sentinel lymph node using combined gamma and ultrasound scanning. Clin Rad. 2014;69:849–52.
Motomura K, Inaji H, Komoike Y, et al. Gamma probe and ultrasonographically-guided fine-needle aspiration biopsy of sentinel lymph nodes in breast cancer patients. Eur J Surg Oncol. 2001;27:141–5.
Okur A, Hennersperger C, Runyan B, et al. FhSPECT-US guided needle biopsy of sentinel lymph nodes in the axilla: is it feasible? Med Image Comput Comput Assist Interv. 2014;17:577–84.
Acknowledgment
This study was funded by a grant from Stater Bros. Charities/Inland Women Fighting Cancer.
Author information
Authors and Affiliations
Corresponding author
Additional information
This study was approved by the Loma Linda University Institutional Review Board and listed at https://ClinicalTrials.gov/ NCT02046057.
Rights and permissions
About this article
Cite this article
Pairawan, S.S., Cora, C., Olaya, W. et al. Percutaneous Sentinel Node Biopsy in Breast Cancer: Results of a Phase 1 Study. Ann Surg Oncol 23, 3330–3336 (2016). https://doi.org/10.1245/s10434-016-5320-2
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-016-5320-2